Drug Approval | March 12, 2022
China approves BeiGene’s tislelizumab
Tislelizumab is now approved for seven indications in China
Tislelizumab is now approved for seven indications in China
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Partners with GITAM University to train 27 employees through a 10-day HR module and make them future-ready
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
It has blended 36 important ingredients for a woman’s health, which has a mix of natural extracts, amino acids, multivitamins and minerals
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Subscribe To Our Newsletter & Stay Updated
